HER2+ Breast Cancer: Applying Recent Data Updates at ASCO 2024 into Clinical Practice - Episode 12

Unmet Needs and Future Direction in HER2+ Breast Cancer

, , , ,

The panel looks to the future landscape for HER2+ breast cancer, highlighting emerging treatment practices and currently unmet needs.

Current Time 0:00
Duration 8:30
Loaded: 0%
Stream Type LIVE
Remaining Time 8:30
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
  • en (Main), selected
EP. 1: Challenges in Diagnosing HER2+ Breast Cancer
EP. 2: Neoadjuvant Treatment Options in HER2+ Early Breast Cancer
EP. 3: Preoperative Monitoring and Surgical Options for HER2+ Patients
EP. 4: Clinical Impact of Subcutaneous Fixed-Dose Pertuzumab – trastuzumab-hyaluronidase in HER2+ Breast Cancer
EP. 5: Standard-of-Care Regimens for First-Line Treatment of HER2+ mBC
EP. 6: Ongoing Clinical Trials in HER2+ Metastatic Breast Cancer
EP. 7: Impact of DESTINY-Breast09 and Other Trials on Clinical Practice and Patient Subsets
EP. 8: Defining HER2 Low and HER2 Ultra-Low: Diagnostic Challenges
EP. 9: Overview of DESTINY-Breast06
EP. 10: Clinical Perspectives on Managing ILD Related to T-DXd
EP. 11: Clinical Considerations and Subsequent Therapies or Sequencing in HER2-Low/HER2+ mBC
Now Viewing
EP. 12: Unmet Needs and Future Direction in HER2+ Breast Cancer

Video content above is prompted by the following:

  • Please provide your closing thoughts about current and future management in HER2+ early stage mBC and HER2-low and ultra-low mBC.
x